LAS VEGAS, NV / ACCESSWIRE / February 27, 2015 / EnzymeBioSystems (OTCBB:ENZB) is a small company with a Big Pharma mentality. "The pharmaceutical industry has changed over the past decade. In the past, Big Pharma would spend a large amount of dollars in researching new pharmaceutical compounds. Today Big Pharma believes it to be more economical to purchase smaller companies that are working to develop and market novel products," stated Ed Zimmerman, III CFO of EnzymeBioSystems.
The management and affiliates of EnzymeBioSystems have over 50-years of experience working for Big Pharma. This experience helps the company operate with the knowledge gained at Big Pharma.
Amooranin is the Company's lead pharmaceutical product. Management believes the product can be used in the prevention of breast cancer and is working to obtain the necessary studies to apply for an Investigational New Drug for the product. Management has sourced the pre-clinical product batch and is negotiating with Contract Research Organizations (CRO) on the two species animal studies.
"We believe we have found the right scientific teams to efficiently complete our required animal studies. We will continue on a regular basis share progress reports. If any major development(s) takes place, we shall file a Form 8-K and press release to inform our valued shareholders," stated Gary Rojewski, CEO.
About EnzymeBioSystems
EnzymeBioSystems produces specialty enzymes and enzyme related products. The Company plans to use enzyme technologies to develop commercial solutions for different applications within the pharmaceutical industry. For more information please visit the company website: http://enzymebiosystems.com/.
Included in this release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Although the company believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations reflected in such forward-looking statements will prove to have been correct. The company's actual results could differ materially from those anticipated in the forward-looking statements.
Contact:
Edward Zimmerman III
EnzymeBioSystems
Phone: (702) 242-0404
[email protected]
SOURCE: EnzymeBioSystems